AGMB AgomAb Therapeutics NV - ADRs representing one common share.
NASDAQ · View on SEC EDGAR ↗ close Oct 2, 2026 10-K/10-Q Apr 23, 2026AGMB Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
AGMB Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
10-Year Performance Revenue, net income, margins and EPS trends
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Not enough fundamentals data to compute this ratio group yet.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | AGMB | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| ROA | -34.7% | · | · | · | |
| ROE | -39.2% | · | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | AGMB | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Current Ratio | 6.5 | · | · | · | |
| Quick Ratio | 4.6 | · | · | · | |
| Interest Coverage | -987.9 | · | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Not enough fundamentals data to compute this ratio group yet.
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Not enough fundamentals data to compute this ratio group yet.
value · ≈ 5Y avg · industry median · verdict relative to median
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 |
|---|---|---|
| R&D Expense | $49M | |
| SG&A Expense | $13M | |
| Operating Income | $-59M | |
| Interest Expense | $60.0K | |
| Interest Income | $2M | |
| Pretax Income | $-63M | |
| Net Income | $-63M | |
| EPS (Basic) | $-143.22 | |
| EPS (Diluted) | $-143.22 | |
| Shares (Basic) | 541,126 | |
| Shares (Diluted) | 541,126 | |
| EBITDA | $-59M |
Balance Sheet
| Metric | Trend | 2025 |
|---|---|---|
| Cash & Equivalents | $86M | |
| Current Assets | $121M | |
| PP&E (Net) | $503.0K | |
| Goodwill | $9M | |
| Intangibles | $20M | |
| Total Assets | $154M | |
| Accounts Payable | $10M | |
| Current Liabilities | $19M | |
| Total Liabilities | $23M | |
| Stockholders' Equity | $131M |
Cash Flow
| Metric | Trend | 2025 |
|---|---|---|
| Operating Cash Flow | $-52M | |
| Investing Cash Flow | $-33M | |
| Financing Cash Flow | $-338.0K |
Profitability
| Metric | Trend | 2025 |
|---|---|---|
| ROA | -34.7% | |
| ROE | -39.2% |
Liquidity & Solvency
| Metric | Trend | 2025 |
|---|---|---|
| Current Ratio | 6.5 | |
| Quick Ratio | 4.6 | |
| Interest Coverage | -987.9 |
Per Share
| Metric | Trend | 2025 |
|---|---|---|
| Cash Flow / Share | $-95.62 | |
| EPS (TTM) | $-143.22 |
Valuation (TTM)
| Metric | Trend | 2025 |
|---|---|---|
| Net Income TTM | $-63M |
We don't have SEC filings for this ticker yet.
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net Income | $-63M | $-46M | $-11M |
| Diluted EPS | $-143.22 | $-107.09 | $-35.63 |
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Current Ratio | 6.5 | · | · |
| Quick Ratio | 4.6 | · | · |
Not enough fundamentals data to build this statement yet.
Institutional owners (13F) 34 filers · $336.7M total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 9 | 7 | 4 | 6 | · |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair. Change vs prior quarter not shown: filer coverage differs too much between these two quarters for a reliable comparison.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| EQT Fund Management S.a r.l. | $66,743,056 | 5,141,992 | 19.82% | Shares |
| Sanofi | $36,124,586 | 2,783,096 | 10.73% | Shares |
| Redmile Group, LLC | $35,486,359 | 2,733,926 | 10.54% | Shares |
| Cormorant Asset Management, LP | $32,000,217 | 2,465,348 | 9.50% | Shares |
| TCG Crossover Management, LLC | $26,650,964 | 2,053,233 | 7.91% | Shares |
| FEDERATED HERMES, INC. | $21,001,640 | 1,618,000 | 6.24% | Shares |
| Nantahala Capital Management, LLC | $20,355,080 | 1,568,188 | 6.04% | Shares |
| Casdin Capital, LLC | $20,119,000 | 1,550,000 | 5.97% | Shares |
| ANDERA PARTNERS | $19,972,352 | 1,538,702 | 5.93% | Shares |
| FMR LLC | $18,933,627 | 1,458,677 | 5.62% | Shares |
| Aberdeen Group plc | $10,990,101 | 846,695 | 3.26% | Shares |
| PERCEPTIVE ADVISORS LLC | $7,788,000 | 600,000 | 2.31% | Shares |
| SAMSARA BIOCAPITAL, LLC | $7,788,000 | 600,000 | 2.31% | Shares |
| Siren, L.L.C. | $5,338,025 | 411,250 | 1.59% | Shares |
| ORBIMED ADVISORS LLC | $2,501,765 | 192,740 | 0.74% | Shares |
| Pfizer Inc | $1,035,750 | 75,000 | 0.31% | Shares |
| ALPS ADVISORS INC | $648,792 | 49,984 | 0.19% | Shares |
| Bellevue Group AG | $639,239 | 49,248 | 0.19% | Shares |
| SEVEN GRAND MANAGERS, LLC | $617,848 | 47,600 | 0.18% | Shares |
| SECTORAL ASSET MANAGEMENT INC | $564,630 | 43,500 | 0.17% | Shares |
| Burkehill Global Management, LP | $454,300 | 35,000 | 0.13% | Shares |
| Quadrature Capital Ltd | $265,584 | 20,461 | 0.08% | Shares |
| TWO SIGMA INVESTMENTS, LP | $234,575 | 18,072 | 0.07% | Shares |
| GOLDMAN SACHS GROUP INC | $153,164 | 11,800 | 0.05% | Shares |
| XTX Topco Ltd | $133,318 | 10,271 | 0.04% | Shares |
| CITIGROUP INC | $123,258 | 9,496 | 0.04% | Shares |
| UBS Group AG | $27,622 | 2,128 | 0.01% | Shares |
| GAMMA Investing LLC | $17,445 | 1,344 | 0.01% | Shares |
| MORGAN STANLEY | $15,576 | 1,200 | 0.00% | Shares |
| BNP PARIBAS FINANCIAL MARKETS | $9,787 | 754 | 0.00% | Shares |
| Larson Financial Group LLC | $9,060 | 698 | 0.00% | Shares |
| HRT FINANCIAL LP | $221 | 17,075 | 0.00% | Shares |
| Caitong International Asset Management Co., Ltd | $26 | 2 | 0.00% | Shares |
| SBI Securities Co., Ltd. | $26 | 2 | 0.00% | Shares |
Activists & 5%+ owners 1 position
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| LSP 7 Cooperatieve U.A., LSP 7 Management B.V. | Feb. 17, 2026 | 10.60% | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 2 insiders · 0 officers · 2 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Naimish Patel | Director | Sept. 11, 2026 A | · | 0 | 0 | $0 |
| Marino Garcia | Director | Sept. 11, 2026 A | · | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
AGMB Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
12-Month Price Target
6 analysts · 2026-09-29Mean target $37.67 +340.0%
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.